Study identifier:D3461R00090
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
Systemic Lupus Erythematosus
N/A
No
Anifrolumab
Female
240
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
PPD
No locations available
Arms | Assigned Interventions |
---|---|
Anifrolumab exposed pregnancies The primary analysis cohort will be prospectively reported pregnancies with anifrolumab exposure anytime from 16 weeks prior to date of conception (DOC) until pregnancy outcome. | - |